<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425279</url>
  </required_header>
  <id_info>
    <org_study_id>BA3011-001</org_study_id>
    <nct_id>NCT03425279</nct_id>
  </id_info>
  <brief_title>CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioAtla, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioAtla, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety,
      tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active
      biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC) in patients with advanced
      solid tumors in Phase 1 and BA3011 alone and in combination with nivolumab in Phase 2.

      Phase 1 of this study will consist of a dose escalation phase (enrollment complete as of Oct
      2019) and a dose expansion phase (still enrolling).

      Phase 2 is targeted to begin in Q3 2020 and will include both adult and adolescents age 12
      and over.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of Treatment-Emergent Adverse Events (Safety and Tolerability of BA3011)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Measured by frequency and severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>DLT will be assessed from first treatment cycle (3 weeks)</time_frame>
    <description>Number of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>[Time Frame: MTD will be assessed from first treatment cycle (3 weeks)]</time_frame>
    <description>Number of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Overall Response Rate (ORR) according to RECIST version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Maximum observed concentration of BA3011</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Area under the concentration versus time curve of BA3011</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of BA3011</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Presence of anti-drug antibodies (ADA)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Sarcoma</condition>
  <condition>Sarcoma, Ewing</condition>
  <condition>Osteosarcoma</condition>
  <condition>Leiomyosarcoma</condition>
  <condition>Synovial Sarcoma</condition>
  <condition>Liposarcoma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Bone Sarcoma</condition>
  <condition>Refractory Sarcoma</condition>
  <arm_group>
    <arm_group_label>BA3011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with nivolumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAB-AXL-ADC</intervention_name>
    <description>Conditionally active biologic anti-AXL antibody drug conjugate</description>
    <arm_group_label>BA3011</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have measurable disease.

          -  Age ≥ 18 years (Phase 1); Age ≥ 12 years (Phase 2)

          -  Adequate renal function

          -  Adequate liver function

          -  Adequate hematological function

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Life expectancy of at least three months.

        Exclusion Criteria:

          -  Patients must not have clinically significant cardiac disease.

          -  Patients must not have known non-controlled CNS metastasis.

          -  Patients must not have received granulocyte colony stimulating factor (G-CSF) or
             granulocyte/macrophage colony stimulating factor support 3 weeks prior to first BA3011
             administration. (Phase 1 only)

          -  Patients must not have had prior therapy with a conjugated or unconjugated auristatin
             derivative/vinca-binding site targeting payload.

          -  Patients must not have Grade 2 or higher peripheral neuropathy.

          -  Patients must not have known human immunodeficiency virus (HIV) infection, active
             hepatitis B and/or hepatitis C.

          -  Patients must not be women who are pregnant or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hazel Buncab, AD, ClinOps</last_name>
    <phone>858-263-1598</phone>
    <phone_ext>8582631598</phone_ext>
    <email>hbuncab@bioatla.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerlee Thomas, Head of Regulatory</last_name>
    <phone>858-263-1598</phone>
    <email>gthomas@bioatla.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tate Closson-Niese</last_name>
      <phone>720-848-0669</phone>
      <email>tate.closson-niese@cuanschutz.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Drees</last_name>
      <phone>720-848-0719</phone>
      <email>EMILY.DREES@CUANSCHUTZ.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Doebele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Health One</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maddie Goral, MD</last_name>
      <phone>720-754-2659</phone>
      <email>Madeline.Goral@SarahCannon.com</email>
    </contact>
    <investigator>
      <last_name>Shiraj Sen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milijana Ugrenovic-Petrovic</last_name>
      <email>Milijana.Ugrenovic-Petrovic@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Soha Riad</last_name>
      <email>Soha.Riad@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mihaela Druta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Schmit, MD</last_name>
      <phone>702-952-3724</phone>
      <email>johanna.schmit@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Braiteh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Mead</last_name>
      <phone>212-304-5292</phone>
      <email>om2301@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Ingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Ricci</last_name>
      <phone>646-888-4303</phone>
      <email>riccik@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Eileen M. O'Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zach Godwin</last_name>
      <phone>503-418-9324</phone>
      <email>godwinz@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Vuky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Burris, MD</last_name>
      <email>Howard.Burris@SarahCannon.com</email>
    </contact>
    <investigator>
      <last_name>Howard Burris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Rodon</last_name>
      <phone>713-792-8927</phone>
      <email>JRodon@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Diep T Tran</last_name>
      <phone>713-792-8927</phone>
      <email>dttran3@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jordi Rodon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>late stage</keyword>
  <keyword>stage 3</keyword>
  <keyword>stage 4</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

